Press Releases

佛羅里達州邁阿密, June 13, 2026 (GLOBE NEWSWIRE) -- 預期 SpaceX (NASDAQ: SPCX) 今日將於 Nasdaq 開始買賣，Defiance ETFs 確認，Defiance Daily 2X Space ETF (Cboe: SPCL) 會在其投資組合中尋求對 SpaceX A 類普通股提供 2 倍每日槓桿曝險，令其成為首隻及唯一在上市首日提供 2 倍 SpaceX 曝險的美國交易所買賣基金 (ETF)。該基金以 135 美元的首次公開招股 (IPO) 價建立其 SpaceX 曝險。

フロリダ州マイアミ発, June 13, 2026 (GLOBE NEWSWIRE) -- スペースX (SpaceX) (NASDAQ: SPCX) が本日NASDAQでの取引を開始する見込みであり、ディファイアンスETFs (Defiance ETFs) は、ディファイアンス・デイリー2XスペースETF (Defiance Daily 2X Space ETF) (Cboe: SPCL) がそのポートフォリオ内で、スペースXのクラスA普通株に対し、1日あたり2倍のレバレッジをかけたエクスポージャーを目指すことを確認した。このことにより、同ETFはIPO当日にスペースXへの2倍のエクスポージャーが設定されている、米国初かつ唯一のETFとなる。同ファンドのスペースXへのエクスポージャーは、IPO価格135ドル (約21,600円) に設定された。

BetOnline issues a USA press announcement focused on No Deposit Casino interest, highlighting casino access, promotional visibility, player support, and responsible participation.

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.^® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options.

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 53,000 people in the U.S. alone, and there are currently no approved treatment options for the disease.